This trial is withdrawn!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Dravet Syndrome or Lennox Gastaut Syndrome
and you are
between 2 and 30
years old
This is an observational trial.
You are contributing to medical knowledge about your condition.
Show me locations

The purpose

The purpose of this study is to determine if cannabidiol (CBD) obtained via the state of Minnesota reduces seizures in patients with severe intractable epilepsy (Dravet Syndrome or Lennox Gastaut Syndrome), and to measure blood levels of CBD to help determine CBD concentration-response characteristics.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02910297. The sponsor of the trial is Gillette Children's Specialty Healthcare and it is looking for 0 volunteers for the current phase.
Official trial title:
The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy